Blueprint gains approval for its drug to treat a rare gastrointestinal cancer

Blueprint gains approval for its drug to treat a rare gastrointestinal cancer

STAT Plus: Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer

By JONATHAN SALTZMAN — BOSTON GLOBE

ADOBE

Blueprint Medicines won approval Thursday of its first drug, a precision medicine that dramatically shrank tumors caused by an ultra-rare form of gastrointestinal cancer.

READ MORE